Cardiac fibroblast derived extracellular matrix

Patent metadata

Field	Value
Publication number	US-12419993-B2
Application number	US-202217929890-A
Country	US
Kind code	B2
Filing date	Sep 6, 2022
Priority date	Sep 7, 2021
Publication date	Sep 23, 2025
Grant date	Sep 23, 2025

Abstract

The disclosure generally relates to methods, cells, and compositions for preparing cardiac extracellular matrix. In particular, provided herein are methods for preparing a cardiac extracellular matrix using SUSD2 High fibroblasts and SUSD2 High myofibroblasts.

First claim

The invention claimed is:

1. A method for preparing a cardiac extracellular matrix, comprising:
(a) selecting SUSD2 High fibroblasts from a population of cardiac fibroblasts; and
(b) plating the SUSD2 High fibroblasts into a culture having a cell density of 100,000 to 500,000 cells per cm 2 , wherein the SUSD2 High fibroblasts secrete a cardiac extracellular matrix that is attached to the surface on which the SUSD2 High fibroblasts are plated.

2. The method of claim 1 , wherein the selecting SUSD2 High fibroblasts from the population of cardiac fibroblasts comprises flow cytometry or immunofluorescence.

3. The method of claim 1 further comprising the steps of contacting the secreted cardiac extracellular matrix with ethylenediaminetetraaceticacid (EDTA), whereby the cardiac extracellular matrix becomes detached from the surface, forming a free floating bioscaffold.

4. The method of claim 1 further comprising the step of contacting the cardiac extracellular matrix with a decellularizing agent, whereby the cardiac extracellular matrix is decellularized.

5. The method of claim 4 , wherein the decellularizing agent comprises peracetic acid, a mixture comprising ammonium hydroxide and octylphenol ethylene oxide (Triton™ X-100), or a mixture comprising Tri-N-Butyl-Phosphate and octylphenol ethylene oxide (Triton™ X-100).

6. The method of claim 1 further comprising the step of seeding the cardiac extracellular matrix with one or more cells that are therapeutic for cardiac disease or injury.

7. The method of claim 6 , wherein the one or more cells that are therapeutic for cardiac disease or injury are selected from the group consisting of skeletal myoblasts, embryonic stem cells (ES), induced pluripotent stem cells (iPS), multipotent adult germline stem cells (maGCSs), bone marrow Mesenchymal stem cells (BMSCs), very small embryonic-like stem cells (VSEL cells), endothelial progenitor cells (EPCs), cardiopoietic cells (CPCs), cardiosphere-derived cells (CDCs), multipotent Is/1+ cardiovascular progenitor cells (MICPs), epicardium-derived progenitor cells (EPDCs), adipose-derived stem cells, human mesenchymal stem cells, human mesenchymal stem cells (derived from iPS or ES cells), skeletal myoblasts, exosomes or combinations thereof.

8. The method of claim 1 further comprising the step of seeding the cardiac extracellular matrix with one or more bioactive proteins that are therapeutic for cardiac disease or injury.

9. The method of claim 8 , wherein the one or more bioactive proteins is a cytokine or a growth factor.

10. A method for preparing a cardiac extracellular matrix, comprising:
(a) selecting SUSD2 High myofibroblasts from a population of cardiac myofibroblasts; and
(b) plating the SUSD2 High myofibroblasts into a culture having a cell density of 100,000 to 500,000 cells per cm 2 , wherein the SUSD2 High myofibroblasts secrete a cardiac extracellular matrix that is attached to the surface on which the SUSD2 High myofibroblasts are plated.

11. The method of claim 10 , wherein the selecting SUSD2 High myofibroblasts from the population of cardiac myofibroblasts comprises flow cytometry or immunofluorescence.

12. The method of claim 10 further comprising the steps of contacting the secreted cardiac extracellular matrix with ethylenediaminetetraaceticacid (EDTA), whereby the cardiac extracellular matrix becomes detached from the surface, forming a free floating bioscaffold.

13. The method of claim 10 further comprising the step of contacting the cardiac extracellular matrix with a decellularizing agent, whereby the cardiac extracellular matrix is decellularized.

14. The method of claim 13 , wherein the decellularizing agent comprises peracetic acid, a mixture comprising ammonium hydroxide and octylphenol ethylene oxide (Triton™ X-100), or a mixture comprising Tri-N-Butyl-Phosphate and octylphenol ethylene oxide (Triton™ X-100).

15. The method of claim 10 , further comprising the step of seeding the cardiac extracellular matrix with one or more cells that are therapeutic for cardiac disease or injury.

16. The method of claim 15 , wherein the or more cells that are therapeutic for cardiac disease or injury are selected from the group consisting of skeletal myoblasts, embryonic stem cells (ES), induced pluripotent stem cells (iPS), multipotent adult germline stem cells (maGCSs), bone marrow Mesenchymal stem cells (BMSCs), very small embryonic-like stem cells (VSEL cells), endothelial progenitor cells (EPCs), cardiopoietic cells (CPCs), cardiosphere-derived cells (CDCs), multipotent Is/1+ cardiovascular progenitor cells (MICPs), epicardium-derived progenitor cells (EPDCs), adipose-derived stem cells, human mesenchymal stem cells, human mesenchymal stem cells (derived from iPS or ES cells), skeletal myoblasts, exosomes or combinations thereof.

17. The method of claim 10 further comprising the step of seeding the cardiac extracellular matrix with one or more bioactive proteins that are therapeutic for cardiac disease or injury.

18. The method of claim 17 , wherein the one or more bioactive proteins is a cytokine or a growth factor.

19. A method of generating a population of SUSD2 High fibroblasts, the method comprising selecting SUSD2 High fibroblasts from a population of cardiac fibroblasts to yield a population of SUSD2 High fibroblasts.

20. The method of claim 19 , wherein the selecting SUSD2 High fibroblasts from the population of cardiac fibroblasts comprises flow cytometry or immunofluorescence.

21. A method of generating a population of SUSD2 High myofibroblasts, the method comprising selecting SUSD2 High myofibroblasts from a population of cardiac myofibroblasts to yield a population of SUSD2 High myofibroblasts.

22. The method of claim 21 , wherein the selecting SUSD2 High myofibroblasts from the population of cardiac myofibroblasts comprises flow cytometry or immunofluorescence.

Assignees

• Wisconsin Alumni Res Found

Inventors

• Schmuck Eric
• Raval Amish
• Roy Sushmita
• Zhou Tianhua

Classifications

• C12N5/0657

  Cardiomyocytes; Heart cells · CPC title

• A61L27/3834

  Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells · CPC title

• C12N2533/90

  Substrates of biological origin, e.g. extracellular matrix, decellularised tissue · CPC title

• A61K35/12

  Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00) · CPC title

• A61L27/3687

  characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents · CPC title